13 junio 2017

PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers .

MADRID, June 13, 2017 /PRNewswire/ .

... According to Dr. Arturo Soto, Director of Clinical Development at the Oncology Business Unit at PharmaMar, "we are very pleased with the positive results obtained in endometrial cancer with lurbinectedin, both as a single agent as in combination with doxorubicin. This favorable data allows us to continue advancing and to set up a pivotal phase III study in agreement with the FDA".

Dr Andrés Poveda, Clinical Area of Gynecologic Oncology, Instituto Valenciano de Oncología, Spain, has presented the results of a dose-ranging phase I study that evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of lurbinectedin with olaparib in advanced solid tumors, where a synergistic activity between the two molecules has been observed.

PharmaMar also presented a comparison between two different clinical studies that suggests that Yondelis® and lurbinectedin are both more active in BRCA 2 than BRCA 1 metastatic breast cancer. ...

Foto : Martin Forster dando explicaciones sobre los resultados del PM1183 Endometrio .